For the first time in history, a stem cell therapy derived from induced pluripotent stem cells (iPSCs) has received regulatory approval anywhere in the world — and it targets one of humanity's most widespread and heartbreaking neurological conditions.
On **March 6, 2026**, Japan's Ministry of Health, Labour and Welfare granted conditional and time-limited approval to **Amchepry** (generic name: raguneprocel), a Parkinson's disease therapy developed by Sumitomo Pharma. The same day, a second iPSC-derived therapy — **RiHEART**, developed by biotech startup Cuorips — received approval for severe heart failure.
Taken together, these are the world's first approved medicines made from iPSCs, a technology pioneered by Japanese scientist **Shinya Yamanaka**, who won the Nobel Prize in 2012 for discovering how to reprogram ordinary adult cells into stem cells capable of becoming any tissue in the body.
**What Amchepry Does**
Parkinson's disease destroys the dopamine-producing neurons deep in the brain. As these neurons die, the brain loses its ability to regulate movement — producing the tremors, rigidity, and loss of motor control that characterise the disease. Today's treatments (mainly levodopa medications) manage symptoms but cannot replace the lost neurons.
Amchepry changes that fundamental equation. The therapy takes **allogeneic iPSC cells** (not from the patient's own body, but from donor cells reprogrammed into a stem cell state) and differentiates them in the laboratory into **dopaminergic neural progenitor cells** — essentially young dopamine neurons, ready to mature.
These cells are then transplanted directly into the patient's brain, where they are designed to mature into fully functional dopamine-producing neurons — **replacing the cells the disease destroyed**.
The application was submitted in August 2025, following an investigator-initiated Phase 1/2 clinical study conducted at **Kyoto University Hospital**. Early results were encouraging: **4 out of 6 patients** evaluated for efficacy showed measurable improvements in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part III OFF score), the gold-standard clinical measure of Parkinson's motor severity.
**The Heart Failure Treatment Too**
RiHEART, developed by Cuorips, targets a different crisis entirely: heart failure severe enough that the heart muscle is failing to pump effectively. The therapy involves placing **sheets of iPSC-derived cardiac muscle cells** directly onto the heart's surface. These cell sheets are designed to support cardiac function by promoting tissue repair and encouraging new blood vessel growth — essentially giving the damaged heart new living scaffolding to work with.
**Why Japan First?**
Japan has a dedicated regulatory framework — the **Act on the Safety of Regenerative Medicine** — specifically designed to get promising regenerative therapies to patients faster than conventional drug pathways. Under conditional and time-limited approval, therapies with promising early safety and efficacy data can reach patients while larger post-marketing studies continue, providing real-world evidence for eventual full approval.
This makes Japan the world's leading jurisdiction for regenerative medicine approvals — and likely to remain so as the iPSC revolution matures.
**The Bigger Picture**
Parkinson's affects approximately **10 million people worldwide**, with 90,000 new diagnoses in the United States alone each year. Heart failure affects an estimated **64 million people globally**.
The approval of Amchepry represents the culmination of more than two decades of iPSC science — from Yamanaka's initial 2006 discovery that ordinary skin cells could be reprogrammed into pluripotent stem cells, through years of work refining how to control which cell type they become, to this first approved therapy reaching patients in 2026.
Yamanaka himself has said the goal of iPSC science was always to create personalised, disease-fighting cell therapies. That goal just became reality. 🧬
*Sources: Sumitomo Pharma press release (March 6, 2026) · Japan Ministry of Health, Labour and Welfare · Parkinson's News Today · Medical News Today · ScienceAlert*
